Isomorphic Labs Shifts to Drug Development

This shift is really about owning the drug, not just selling the tool that helps design it. In the partnership model, Isomorphic gets research fees, milestones, and possible royalties, but the pharma partner controls the program and keeps most of the economics if a drug works. Building its own pipeline, adding a chief medical officer, opening in Cambridge, and raising $2.1B all point to a company preparing to take molecules through preclinical and clinical development itself.

• The operating model is becoming more vertically integrated. Isomorphic describes a stack that starts with target and molecule design in IsoDDE, then moves into experimental validation and selected internal programs aimed at oncology and immunology, which is much closer to a biotech workflow than a software vendor workflow.
  2 isomorphiclabs 3 isomorphiclabs 5 wired
• The economic trade off is simple. Service style collaborations can add up to large headline values, nearly $3B across Lilly and Novartis excluding royalties, but those deals spread upside across many years and leave the biggest payoff with the company that owns the approved medicine.
  1 isomorphiclabs 6 sacra
• This also puts Isomorphic into a more demanding competitive set. Recursion after combining with Exscientia already spans automated labs, chemistry, and clinical programs, which shows where value capture in AI drug discovery is heading, from selling discovery access toward building and advancing proprietary assets.
  7 sacra 8 sacra

The next phase is measured less by partnership signings and more by named candidates, IND filings, and early human data. If Isomorphic can turn its design engine into internally owned clinical assets, it moves from being a high end discovery partner to being a real tech enabled pharmaceutical company with much larger value per successful program.